CanSino Biologics Inc.
Other OTCTotal Valuation
CanSino Biologics Inc. carries a market capitalization of 1.05B, placing it among publicly traded companies globally. Its enterprise value stands at 2.79B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.05B |
| Enterprise Value | 2.79B |
Share Statistics
CanSino Biologics Inc. currently has 247.45M shares outstanding.
| Shares Outstanding | 247.45M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 6.76, and the price-to-book ratio stands at 0.81.
| PE Ratio | N/A |
| PS Ratio | 6.76 |
| PB Ratio | 0.81 |
| P/TBV Ratio | 0.84 |
| P/FCF Ratio | 8.53 |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 4.57 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 5.07 |
Financial Position
CanSino Biologics Inc. maintains a current ratio of 2.38, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 43.43, indicating elevated leverage, while an interest coverage ratio of -13.49 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.38 |
| Quick Ratio | 1.85 |
| Debt / Equity | 43.43 |
| Debt / EBITDA | -2.41 |
| Interest Coverage | -13.49 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -9.61 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.28 |
Taxes
| Income Tax | -9.32M |
| Effective Tax Rate | N/A |
Stock Price Statistics
CanSino Biologics Inc.'s stock has declined approximately -6.25% over the past 52 weeks. The 50-day moving average sits at 3.82, while the 200-day moving average is 4.83.
| Beta (5Y) | N/A |
| 52-Week Price Change | -6.25% |
| 50-Day Moving Average | 3.82 |
| 200-Day Moving Average | 4.83 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, CanSino Biologics Inc. generated 609.52M in revenue and converted that into -866.68M in net income, yielding earnings per share of -3.71. EBITDA reached -911.71M, while operating income came in at -911.71M.
| Revenue | 609.52M |
| Gross Profit | 87.62M |
| Operating Income | -911.71M |
| Pretax Income | -924.74M |
| Net Income | -866.68M |
| EBITDA | -911.71M |
| EBIT | -911.71M |
| Earnings Per Share (EPS) | -3.71 |
Balance Sheet
CanSino Biologics Inc. holds 3.53B in cash and equivalents against 2.20B in total debt, resulting in a net debt position of 453.69M. Total book value stands at 5.06B, with working capital of 2.63B providing operational flexibility.
| Cash & Cash Equivalents | 3.53B |
| Total Debt | 2.20B |
| Net Debt | 453.69M |
| Equity (Book Value) | 5.06B |
| Book Value Per Share | 20.54 |
| Working Capital | 2.63B |
Cash Flow
After subtracting -483.09M in capital expenditures, free cash flow totaled -483.09M - equivalent to -1.96 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -483.09M |
| Free Cash Flow | -483.09M |
| FCF Per Share | -1.96 |
Margins
CanSino Biologics Inc. operates with a gross margin of 14.38, reflecting its pricing power and cost economics. The operating margin of -149.58 and net profit margin of -142.19 provide insight into operational efficiency.
| Gross Margin | 14.38 |
| Operating Margin | -149.58 |
| Pretax Margin | -151.72 |
| Profit Margin | -142.19 |
| EBITDA Margin | -149.58 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -2.46 |
| FCF Yield | 11.73 |
Scores
CanSino Biologics Inc. posts an Altman Z-Score of 0.59, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.59 |